Compare ESP & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESP | JSPR |
|---|---|---|
| Founded | 1928 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.8M | 48.1M |
| IPO Year | N/A | N/A |
| Metric | ESP | JSPR |
|---|---|---|
| Price | $46.72 | $1.85 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $21.44 |
| AVG Volume (30 Days) | 14.9K | ★ 780.0K |
| Earning Date | 02-11-2026 | 11-10-2025 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | ★ 28.72 | N/A |
| EPS | ★ 3.16 | N/A |
| Revenue | ★ $42,600,530.00 | N/A |
| Revenue This Year | $9.16 | N/A |
| Revenue Next Year | $5.68 | N/A |
| P/E Ratio | $14.83 | ★ N/A |
| Revenue Growth | ★ 4.90 | N/A |
| 52 Week Low | $24.85 | $1.39 |
| 52 Week High | $55.00 | $22.52 |
| Indicator | ESP | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 66.01 | 51.78 |
| Support Level | $46.27 | $1.73 |
| Resistance Level | $47.77 | $1.85 |
| Average True Range (ATR) | 1.37 | 0.11 |
| MACD | 0.19 | 0.02 |
| Stochastic Oscillator | 81.68 | 67.61 |
Espey Manufacturing & Electronics Corp designs, develops, tests, and manufactures specialized military and rugged industrial power supplies and transformers for use in harsh or severe environment applications. Its products and solutions include power converters, power conditioning, high-voltage radar, contract manufacturing, custom engineering, and others. The applications of these products include AC and DC locomotives, shipboard power, shipboard radar, airborne power, ground-based radar, and ground mobile power.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.